Research programme: epigenetic therapeutics - Gilead

Drug Profile

Research programme: epigenetic therapeutics - Gilead

Latest Information Update: 13 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator EpiTherapeutics
  • Developer Gilead Sciences
  • Class Small molecules
  • Mechanism of Action Histone deacetylase inhibitors; Histone methyltransferase inhibitors; Methyltransferase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Research Breast cancer; Prostate cancer

Most Recent Events

  • 06 May 2015 EpiTherapeutics has been acquired by Gilead Sciences
  • 20 Dec 2012 Preclinical development is ongoing in Denmark
  • 11 Feb 2011 Preclinical development is ongoing in Denmark
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top